Margaret E. Wierman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Margaret E. Wierman has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Katja Kiseljak-Vassiliades
University of Colorado Anschutz Medical Campus 6 Aurora, CO
56 shared publications - Craig J. Thomas
National Institutes of Health
34 shared publications - Jaydira Del Rivero
Developmental Therapeutics Branch, National Cancer Institute, Bethesda, MD 20892, USA
34 shared publications - Nitin Roper
National Cancer Institute 1 Developmental Therapeutics Branch, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
34 shared publications - Suresh Kumar
National Cancer Institute 1 Developmental Therapeutics Branch, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
34 shared publications - Yasuhiro Arakawa
Jikei University School of Medicine 5 Tokyo, Tokyo
34 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
Combination Therapy with AKT and MEK Inhibitors is Effective in Patient-Derived Models of Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare, aggressive, chemoresistant malignancy with limited effective systemic therapies and few recurrent actionable oncogenic drivers. Although IGF-2 is overexpressed in approximately 80% of ACCs, clinical inhibition of the IGF-1R/InsR axis has not improved outcomes. To identify clinically tractable combination strategies that enhance IGF-1R/InsR inhibition in ACC, we performed a quantitative high-throughput combinatorial screen of 2,803 mechanistically annotated oncology compounds with the IGF 1R/InsR inhibitor linsitinib in an ACC cell line. Downstream effects of IGF-1R/InsR signaling were assessed to identify actionable nodes for combination targeting. Candidate combinations were validated using short-term ACC patient-derived organoids (PDOs) and patient-derived xenograft (PDX) models. The screen identified MAPK pathway inhibitors—particularly MEK inhibition—as the top synergistic partners with IGF-1R/InsR inhibition. Genetic or pharmacologic inhibition of IGF-1R/InsR and MEK signaling suppressed ACC growth in vitro. Downstream profiling of IGF-1R/InsR signaling identified AKT as a major effector, supporting direct AKT targeting as a translatable substitute for IGF-1R/InsR inhibition in ACC. Accordingly, the AKT inhibitor capivasertib synergized with the MEK inhibitor cobimetinib in ACC cell lines and six ACC PDO models. In vivo, combined AKT and MEK inhibition reduced tumor growth more than either agent alone in an ACC xenograft and two ACC chemotherapy-resistant PDX models with acceptable tolerability. These data identify AKT as a critical survival pathway in ACC and support combined AKT and MEK inhibition with FDA-approved agents as a therapeutic approach for chemotherapy-resistant ACC.
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
Open AccessCombination Therapy with AKT and MEK Inhibitors is Effective in Patient-Derived Models of Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare, aggressive, chemoresistant malignancy with limited effective systemic therapies and few recurrent actionable oncogenic drivers. Although IGF-2 is overexpressed in approximately 80% of ACCs, clinical inhibition of the IGF-1R/InsR axis has not improved outcomes. To identify clinically tractable combination strategies that enhance IGF-1R/InsR inhibition in ACC, we performed a quantitative high-throughput combinatorial screen of 2,803 mechanistically annotated oncology compounds with the IGF 1R/InsR inhibitor linsitinib in an ACC cell line. Downstream effects of IGF-1R/InsR signaling were assessed to identify actionable nodes for combination targeting. Candidate combinations were validated using short-term ACC patient-derived organoids (PDOs) and patient-derived xenograft (PDX) models. The screen identified MAPK pathway inhibitors—particularly MEK inhibition—as the top synergistic partners with IGF-1R/InsR inhibition. Genetic or pharmacologic inhibition of IGF-1R/InsR and MEK signaling suppressed ACC growth in vitro. Downstream profiling of IGF-1R/InsR signaling identified AKT as a major effector, supporting direct AKT targeting as a translatable substitute for IGF-1R/InsR inhibition in ACC. Accordingly, the AKT inhibitor capivasertib synergized with the MEK inhibitor cobimetinib in ACC cell lines and six ACC PDO models. In vivo, combined AKT and MEK inhibition reduced tumor growth more than either agent alone in an ACC xenograft and two ACC chemotherapy-resistant PDX models with acceptable tolerability. These data identify AKT as a critical survival pathway in ACC and support combined AKT and MEK inhibition with FDA-approved agents as a therapeutic approach for chemotherapy-resistant ACC.
- 15 August 2026
- Published by The Endocrine Society in Endocrinology
- Vol. 167 (10)
Comprehensive profiling of OTSSP167 action in adrenocortical carcinoma
Purpose: Adrenocortical carcinoma (ACC) is an aggressive malignancy with no approved targeted therapy and poor outcomes. Methods: Using multiple patient-derived xenograft (PDX) and cell line xenograft (CLX) models, and a newly developed PDX model (CUACC9), we investigated the potential action of the multikinase inhibitor OTSSP167 for treatment of ACC. Results: OTSSP167 effectively reduced tumor growth in wild-type TP53 (CUACC1) and mutant TP53 (H295R, CUACC9) in vivo tumor models. Immunohistochemical analysis of treated tumors verified apoptosis via caspase activation as a mechanism of OTSSP167 action. Further evaluation of downstream effectors via RNAseq and a reverse phase protein array (RPPA), using ACC cell lines matching the in vivo genetic diversity, demonstrated that OTSSP167 impeded cell cycle via G2/M arrest independent of TP53 status. In TP53 mutant lines, OTSSP167 enhanced DNA damage and inhibited protein synthesis. RSK1 was identified as a direct target of OTSSP167 activity in vitro. OTSSP167 also induced the G2/M checkpoint protein, WEE1, activation in all models, indicating an early adaptive response. Combining the WEE1 inhibitor AZD1775 with OTSSP167 significantly enhanced cytotoxicity in TP53 mutant lines, and reduced tumor growth in a TP53 mutant ACC model. Conclusion: Together these findings establish the feasibility of using OTSSP167 in ACC, especially in TP53 mutant ACC tumors. In addition, this study demonstrates the possibility of targeting the early adaptive response subsequent to exposure to OTSSP167 treatment. Our findings provide strong rationale for a future phase I clinical trial in ACC.
- 15 August 2026
- Published by The Endocrine Society in Endocrinology
- Vol. 167 (10)
Comprehensive profiling of OTSSP167 action in adrenocortical carcinoma
Purpose: Adrenocortical carcinoma (ACC) is an aggressive malignancy with no approved targeted therapy and poor outcomes. Methods: Using multiple patient-derived xenograft (PDX) and cell line xenograft (CLX) models, and a newly developed PDX model (CUACC9), we investigated the potential action of the multikinase inhibitor OTSSP167 for treatment of ACC. Results: OTSSP167 effectively reduced tumor growth in wild-type TP53 (CUACC1) and mutant TP53 (H295R, CUACC9) in vivo tumor models. Immunohistochemical analysis of treated tumors verified apoptosis via caspase activation as a mechanism of OTSSP167 action. Further evaluation of downstream effectors via RNAseq and a reverse phase protein array (RPPA), using ACC cell lines matching the in vivo genetic diversity, demonstrated that OTSSP167 impeded cell cycle via G2/M arrest independent of TP53 status. In TP53 mutant lines, OTSSP167 enhanced DNA damage and inhibited protein synthesis. RSK1 was identified as a direct target of OTSSP167 activity in vitro. OTSSP167 also induced the G2/M checkpoint protein, WEE1, activation in all models, indicating an early adaptive response. Combining the WEE1 inhibitor AZD1775 with OTSSP167 significantly enhanced cytotoxicity in TP53 mutant lines, and reduced tumor growth in a TP53 mutant ACC model. Conclusion: Together these findings establish the feasibility of using OTSSP167 in ACC, especially in TP53 mutant ACC tumors. In addition, this study demonstrates the possibility of targeting the early adaptive response subsequent to exposure to OTSSP167 treatment. Our findings provide strong rationale for a future phase I clinical trial in ACC.
- Open Access
- 1 April 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (7) , 1801-1812
Glucocorticoid reduction after starting crinecerfont in adult patients with classic CAH: practical perspectives
Context: Crinecerfont, a first-in-class corticotropin-releasing factor type 1 receptor antagonist, is FDA-approved as an adjunct to the physiologic glucocorticoid (GC) required to treat the underlying adrenal insufficiency in patients (≥4 years old) with classic congenital adrenal hyperplasia (CAH). By reducing elevated adrenocorticotropic hormone, crinecerfont controls excess adrenal androgens, thereby enabling lower GC doses. However, there are no published recommendations for how to reduce supraphysiologic GC doses after initiating crinecerfont. This manuscript aims to provide a framework developed by experienced endocrinologists for reducing supraphysiologic GC doses in patients taking crinecerfont. Evidence Acquisition: An experienced panel of 11 endocrinologists discussed strategies and considerations when reducing GC doses and developed an algorithm to guide GC dose reductions after introducing crinecerfont in adults with CAH. Evidence Synthesis: Approaches to GC reduction should be individualized based on the patient's therapeutic goals, cortisol needs, lifestyle preferences, and the clinician's experience to set appropriate targets for clinical parameters, androgens, and GC dose regimen. In general, GC doses should be reduced gradually to minimize the risks of developing symptoms of GC withdrawal or adrenal insufficiency. GC doses should be adjusted to the lowest level needed to maintain androgens at goal, without reducing below what is needed for cortisol replacement. Practical considerations during GC dose reduction include switching from longer- to shorter-acting GCs (eg, from dexamethasone to hydrocortisone), optimizing dose distribution to mimic normal circadian cortisol exposure, and consolidating or eliminating doses to improve adherence. Conclusion: This framework for reducing supraphysiologic GC doses in adult patients taking crinecerfont may become increasingly relevant as treatment of CAH shifts toward physiologic GC replacement with adjunctive control of adrenal androgens.
- 1 April 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (7) , 1801-1812
Open AccessGlucocorticoid reduction after starting crinecerfont in adult patients with classic CAH: practical perspectives
Context: Crinecerfont, a first-in-class corticotropin-releasing factor type 1 receptor antagonist, is FDA-approved as an adjunct to the physiologic glucocorticoid (GC) required to treat the underlying adrenal insufficiency in patients (≥4 years old) with classic congenital adrenal hyperplasia (CAH). By reducing elevated adrenocorticotropic hormone, crinecerfont controls excess adrenal androgens, thereby enabling lower GC doses. However, there are no published recommendations for how to reduce supraphysiologic GC doses after initiating crinecerfont. This manuscript aims to provide a framework developed by experienced endocrinologists for reducing supraphysiologic GC doses in patients taking crinecerfont. Evidence Acquisition: An experienced panel of 11 endocrinologists discussed strategies and considerations when reducing GC doses and developed an algorithm to guide GC dose reductions after introducing crinecerfont in adults with CAH. Evidence Synthesis: Approaches to GC reduction should be individualized based on the patient's therapeutic goals, cortisol needs, lifestyle preferences, and the clinician's experience to set appropriate targets for clinical parameters, androgens, and GC dose regimen. In general, GC doses should be reduced gradually to minimize the risks of developing symptoms of GC withdrawal or adrenal insufficiency. GC doses should be adjusted to the lowest level needed to maintain androgens at goal, without reducing below what is needed for cortisol replacement. Practical considerations during GC dose reduction include switching from longer- to shorter-acting GCs (eg, from dexamethasone to hydrocortisone), optimizing dose distribution to mimic normal circadian cortisol exposure, and consolidating or eliminating doses to improve adherence. Conclusion: This framework for reducing supraphysiologic GC doses in adult patients taking crinecerfont may become increasingly relevant as treatment of CAH shifts toward physiologic GC replacement with adjunctive control of adrenal androgens.
- 16 June 2025
- Published by The Endocrine Society in Endocrine Reviews
- Vol. 46 (5) , 736-759
Contraceptive Selection for the Endocrine Patient: What an Endocrinologist Should Know
Although endocrinologists specialize in the management of hormones, they often lack sufficient training in the appropriate use of the diverse array of available contraceptive options. All medical providers should possess a fundamental understanding of contraceptive methods for pregnancy prevention, but endocrinologists should have a deeper understanding of birth control possibilities due to the useful role of hormone-containing contraception in managing endocrine and metabolic disorders. This manuscript outlines the history of contraception and then evaluates both existing and emerging birth control options for women and men. Delving further, this review also explores the impact of individual sex steroids—estrogens, progestins, and androgens—used in hormonal contraceptive methods. In addition to their role as contraceptives, the influence of these exogenous hormones on the hypothalamic-pituitary-gonadal axis warrants careful consideration. These effects extend beyond pregnancy prevention and can be instrumental in regularizing menses, sex steroid replacement, and androgen suppression. Finally, this review provides tailored suggestions for contraceptive usage in patients with endocrine disorders, ensuring comprehensive care and informed decision-making in clinical practice.
- 16 June 2025
- Published by The Endocrine Society in Endocrine Reviews
- Vol. 46 (5) , 736-759
Contraceptive Selection for the Endocrine Patient: What an Endocrinologist Should Know
Although endocrinologists specialize in the management of hormones, they often lack sufficient training in the appropriate use of the diverse array of available contraceptive options. All medical providers should possess a fundamental understanding of contraceptive methods for pregnancy prevention, but endocrinologists should have a deeper understanding of birth control possibilities due to the useful role of hormone-containing contraception in managing endocrine and metabolic disorders. This manuscript outlines the history of contraception and then evaluates both existing and emerging birth control options for women and men. Delving further, this review also explores the impact of individual sex steroids—estrogens, progestins, and androgens—used in hormonal contraceptive methods. In addition to their role as contraceptives, the influence of these exogenous hormones on the hypothalamic-pituitary-gonadal axis warrants careful consideration. These effects extend beyond pregnancy prevention and can be instrumental in regularizing menses, sex steroid replacement, and androgen suppression. Finally, this review provides tailored suggestions for contraceptive usage in patients with endocrine disorders, ensuring comprehensive care and informed decision-making in clinical practice.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Figure 1 related to Figure 2
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Figure 1 related to Figure 2
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Figure 2 related to Figure 4
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Figure 2 related to Figure 4
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Table 2, related to Figure 5 and 6.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Table 2, related to Figure 5 and 6.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Figure 3 related to Figure 8
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Supplement Figure 3 related to Figure 8
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Table S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Table S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples